TY - JOUR
T1 - A review of phosphodiesterase type 5 inhibitors
AU - Schellack, Natalie
AU - Agoro, A.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction. However, sildenafil is also registered for use in the treatment of pulmonary hypertension. Newer studies are investigating the use of these drugs for other conditions, including hypertension, ischaemia or reperfusion injury, myocardial infarction, cardiac hypertrophy, heart failure and other peripheral circulatory conditions, e.g. Raynaud's disease. The article provides a broad overview of the mechanism of action, indications, pharmacokinetics and side-effects of these agents. © Medpharm.
AB - Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction. However, sildenafil is also registered for use in the treatment of pulmonary hypertension. Newer studies are investigating the use of these drugs for other conditions, including hypertension, ischaemia or reperfusion injury, myocardial infarction, cardiac hypertrophy, heart failure and other peripheral circulatory conditions, e.g. Raynaud's disease. The article provides a broad overview of the mechanism of action, indications, pharmacokinetics and side-effects of these agents. © Medpharm.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84901285123&origin=inward
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84901285123&origin=inward
U2 - 10.1080/20786204.2014.10855345
DO - 10.1080/20786204.2014.10855345
M3 - Literature review
SN - 2078-6190
SP - 96
EP - 101
JO - South African Family Practice
JF - South African Family Practice
ER -
